Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: Cancer and Leukemia Group B study 39901

Journal of Thoracic Oncology

Volumn 3, Issue 2, 2008, Pages 158-162

  Graziano, Stephen L ^a   Herndon II, James E ^b   Socinski, Mark A ^c   Wang, Xiaofei ^b   Watson, Dorothy ^b   Vokes, Everett ^d   Green, Mark R ^e  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e CCOP Southeast Cancer Control Consortium   (United States)

Author keywords

Chemotherapy; Extensive stage; Paclitaxel; Small cell lung cancer

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DERMATITIS; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE;

EID: 40049096148     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318161225e     Document Type: Article

References (25)

1. A Jemal R Siegel E Ward Cancer statistics, 2006 CA Cancer J Clin 56 2006 106 130
2. R Govindan N Page D Morgensztern Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database J Clin Oncol 24 2006 4539 4544
3. JP Pignon R Arriagada D Ihde A meta-analysis of thoracic radiotherapy for small-cell lung cancer N Engl J Med 327 2002 1618 1624
4. A Auperin R Arriagada JP Pignon Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group N Engl J Med 341 1999 476 484
5. JH Schiller S Adak D Cella Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593—a phase III trial of the Eastern Cooperative Oncology Group J Clin Oncol 19 2001 2114 2122
6. NH Hanna AB Sandler PJ Loehrer Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study Ann Oncol 13 2002 95 102
7. K Noda Y Nishiwaki M Kawahara Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 2002 85 91
8. NH Hanna PA Bunn Jr C Langer Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer J Clin Oncol 24 2006 2038 2043
9. RJ Kirsching JP Grill RS Marks Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group Am J Clin Oncol 22 1999 517 522
10. DS Ettinger DM Finkelstein RP Sarma DH Johnson Phase II study of paclitaxel in patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group study J Clin Oncol 13 1995 1430 1435
11. EF Smit E Fokkema B Biesma Phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer Br J Cancer 77 1995 347 351
12. N Yamamoto J Tsurutani N Yoshimura Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer Anticancer Res 26 2006 777 781
13. D Fennelly C Aghahanian F Shapiro Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer J Clin Oncol 15 1997 187 192
14. AD Seidman CA Hudis J Albanell Dose-dense therapy with weekly 1-hour paclitaxel infusion in the treatment of metastatic breast cancer J Clin Oncol 16 1998 3353 3361
15. AY Chang J Rubins R Asbury Weekly paclitaxel in advanced non-small cell lung cancer Semin Oncol 28 2001 10 13
16. W Akerley M Glantz H Choy Phase I trial of weekly paclitaxel in advanced lung cancer J Clin Oncol 16 1998 153 158
17. W Akerley JE Herndon MJ Egorin Weekly, high-dose paclitaxel in advanced lung carcinoma: a Phase II study with pharmacokinetics by the Cancer and Leukemia Group B Cancer 97 2003 2480 2486
18. P Therasse SG Arbuck EA Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
19. EL Kaplan P Meier Non-parametric estimation from incomplete observation J Am Stat Assoc 53 1985 457 481
20. HJ Groen E Fokkema B Biesma Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross resistant schedule J Clin Oncol 17 1999 927 932
21. S Kakolyris D Mavroudis N Tsavaris Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study Ann Oncol 12 2001 193 197
22. G Sonpavde R Ansari P Walker Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial Am J Clin Oncol 23 2000 68 70
23. HB Neill JE Herndon II AA Miller Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732 J Clin Oncol 23 2005 3752 3759
24. D Mavroudis E Papadakis M Veslemes A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer Ann Oncol 12 2001 463 470
25. AD Seidman DL Berry C Cirrincione CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1 hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC Proc Am Soc Clin Oncol 22 2005 6S